The round was led by IAG Capital Partners (IAG) with participation from the company's current investors. DeepCure has raised more than $72 million in financing since its inception.

DeepCure was founded by researchers at MIT to accelerate breakthrough therapies using artificial intelligence (AI) and AI-enabling technologies to innovate small molecule discovery. The company is based in Boston, MA, and its engineers, chemists, and biologists collaborate on hard problems to find solutions that will have an enormous impact on patient health.